Status:
COMPLETED
Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma
Lead Sponsor:
Samsung Medical Center
Conditions:
Hepatocellular Carcinoma
Renal Cell Carcinoma
Eligibility:
All Genders
Brief Summary
All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study. No additional treatment or intervention will be conducted excep...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study
Exclusion
Key Trial Info
Start Date :
August 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2013
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01482520
Start Date
August 1 2008
End Date
October 1 2013
Last Update
May 14 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea